Osteoporosis is the disorder, where risen weakness of bone increases the risk of breakage of bone. It has no symptoms; the key consequences of it are the increased risk of the bone fracture. Typically fracture occurs in rib, wrist, hip and vertebral column.
An exclusive interview was held between an industry analysts and a market researcher. Following key points have been excerpted from the interview.
What according to you will be the performance of the global anti-osteoporosis therapy and fracture healing market in recent years?
Well, various drug types are effective for the healing of bone fracture and osteoporosis, however bisphosphonates is the drug, which is widely adopted for the treatment of this disease. The bisphosphonates have procured nearly two-fifth share of the whole market and is anticipated to reach valuation of almost US$ 6 Bn by the end of 2026. Further, expenditure for the cure of this disease is likely to fuel growth of the anti-osteoporosis therapy and fracture healing market. The market is likely to witness expansion at 5 % CAGR over the forecast period (2018-2026).
According to you, what are the factors influencing growth of the market?
Increasing prevalence of osteoporosis is recognized to be an important factor fueling the growth of the global market. Further, increase in the number of patients is likely to increase demand for therapy and drugs. Demand for drugs required to heal osteoporosis is consistently increasing owing to absence of alternatives such as surgery. Apropos statistics calculated by International Osteoporosis Foundation, nearly half of the global bone fracture incidents are likely to occure in APAC region by the end of 2050. Thus, large occurrence and incidents rate of such disease is likely to fuel expansion of the market over the foreseeable future.
Which drug do you think is likely to lead the market?
Well, the market has been segmented into calcitonin, bisphosphonates, hormone or estrogen replacement therapy, anabolics, and biologics on the basis of drug type. According to the report published by FMI, the bisphosphonates is likely to lead the market and retain its dominance in the market over the assessment period. This drug is likely to reach valuation of approximately US$ 6 Bn by the end of 2026.
Why do you think North America will dominate the market?
The market in the North America is likely to lead in the global market and is anticipated to retain its dominance in the global market throughout the assessment period. The market in the North America region is likely to reach valuation of approximately US$ 5 Bn by the end of forecast period. The growth of the market in this region is attributed to the increasing investments in the R&D operations for discovery of more and more new drugs.
How will describe growth of the market in APAC region?
The market in the APAC region is likely to exhibit high CAGR in the same duration. China and India are the largest markets for the production of new and more drugs for the treatment of this disease. This growth in India and China is likely to cater to the expansion of market in the APAC region. Further, increasing awareness regarding osteoporosis is the key factor influencing growth of the market over the forecast period. Increasing geriatric population and vast pool of patients are another key factors influencing growth of the market.
What according to you are the leading players in the market?
Typically, Novartis, Johnson and Johnson, GlaxoSmithKline PLC are considered as the leading players in the market. However, Roche, Pfizer, MERCK, and AMGEN are some other players that have consolidated their footprints in the market.
Request Report Sample@ https://www.futuremarketinsights.com/reports/sample/rep-gb-1008